Kaz's Avatar

PCI-32765 (ibrutinib) - Kaz

Clinical Trial Associated with Slow Growing, Chronic Lymphocytic Leukemia . Posted on February 17, 2013 View this journey (4 Experiences)

Currently in a Clinical Trial run through Ohio State University. This trial tests the effects of PCI-32765 on CLL.

I had to end this trial after 4+ years as my CCL has come back. The CLL has "mutated" resulting in a recurrence. OSU provided with mith multiple options and continues to support me as I move to my next treatment.

This medicine was very good for me with limited side effects.

It was been very successful for me. I was diagnosed in September 2011 with Stage 4 CLL. This was the 3rd time I have been in Stage 4 in the past 5 years. I began my treatment using PCI-32765 (ibrutinib) in 10/11. My quality of life has been raised throughout this treatment. In 2013, I had less than 1% CLL in my blood. Ibrutinib has been an amazing successful drug for me.

Dr. Byrd is a quality person and an excellent doctor. I feel blessed to have been able to join this trial.

Read and answer Slow Growing, Chronic Lymphocytic Leukemia questions.